# OnCo record jesus-berdeja (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/jesus-berdeja/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "jesus-berdeja" ;
  schema:name "Jesús G. Berdeja"@en ;
  schema:description "Led CARTITUDE-1, the trial that brought ciltacabtagene autoleucel, the most active myeloma CAR-T, to approval."@en ;
  schema:url <https://onco.cc/people/jesus-berdeja/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Berdeja%20JG%5BAuthor%5D%20ciltacabtagene> ;
  onco:tag "myeloma", "car-t", "community-research" ;
  schema:jobTitle "Director of Myeloma Research, Greco-Hainsworth Centers for Research, Tennessee Oncology; Sarah Cannon Research Institute" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/bcma/> ;
  onco:drugs <https://onco.cc/drugs/ciltacabtagene-autoleucel/> ;
  onco:institutions <https://onco.cc/institutions/tennessee-oncology/> ;
  onco:trials <https://onco.cc/trials/cartitude-1/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-cartitude-1-cilta-cel-lancet-2021/> ;
  schema:affiliation <https://onco.cc/institutions/tennessee-oncology/> .